Drugs / KSI-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06990399 | Jul 2025 → Apr 2027 expected | macular retinal edema | Kodiak Sciences Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06996080 | Jul 2025 → Feb 2027 expected | macular retinal edema | Kodiak Sciences Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990399 ↗ |
| Route | Intravitreal | “Intravitreal injection of KSI-101 5 mg once every 4 weeks” NCT06990399 ↗ |